IN2014MN02459A - - Google Patents

Info

Publication number
IN2014MN02459A
IN2014MN02459A IN2459MUN2014A IN2014MN02459A IN 2014MN02459 A IN2014MN02459 A IN 2014MN02459A IN 2459MUN2014 A IN2459MUN2014 A IN 2459MUN2014A IN 2014MN02459 A IN2014MN02459 A IN 2014MN02459A
Authority
IN
India
Prior art keywords
compounds
administration
preparing
disclosure
processes
Prior art date
Application number
Other languages
English (en)
Inventor
John O Link
Jeromy J Cottell
Martin Teresa Alejandra Trejo
Elizabeth M Bacon
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of IN2014MN02459A publication Critical patent/IN2014MN02459A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2459MUN2014 2012-05-16 2013-05-15 IN2014MN02459A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647966P 2012-05-16 2012-05-16
US13/831,116 US20130309196A1 (en) 2012-05-16 2013-03-14 Antiviral compounds
PCT/US2013/041201 WO2013173488A1 (en) 2012-05-16 2013-05-15 Antiviral compounds inhibitors of hcv ns5b

Publications (1)

Publication Number Publication Date
IN2014MN02459A true IN2014MN02459A (es) 2015-07-10

Family

ID=49581469

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2459MUN2014 IN2014MN02459A (es) 2012-05-16 2013-05-15

Country Status (19)

Country Link
US (5) US20130309196A1 (es)
EP (2) EP3239153B1 (es)
JP (2) JP6209209B2 (es)
KR (2) KR20200017557A (es)
CN (3) CN106432254B (es)
AU (3) AU2013262874B2 (es)
BR (1) BR112014028221B1 (es)
CA (1) CA2873485C (es)
EA (2) EA034749B1 (es)
ES (2) ES2628350T3 (es)
HK (2) HK1205126A1 (es)
IL (1) IL235645A0 (es)
IN (1) IN2014MN02459A (es)
MX (1) MX362060B (es)
PL (2) PL2850085T3 (es)
PT (2) PT3239153T (es)
SG (2) SG10201703451RA (es)
SI (2) SI3239153T1 (es)
WO (1) WO2013173488A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358979C2 (ru) 2003-05-30 2009-06-20 Фармассет, Инк. Модифицированные фторированные аналоги нуклеозида
KR20190140486A (ko) 2010-11-17 2019-12-19 길리애드 파마셋 엘엘씨 항바이러스 화합물
PT3431477T (pt) 2011-11-16 2020-12-15 Gilead Pharmasset Llc Imidazolilimidazolos condensados como compostos antivirais
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015030854A1 (en) * 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TW202014413A (zh) * 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
EP3164405A4 (en) * 2014-07-02 2018-05-23 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
ES2926579T3 (es) 2016-05-05 2022-10-27 Laurus Labs Ltd Proceso para la preparación de compuestos intermedios útiles en la preparación de inhibidores del virus de la Hepatitis C (VHC)
CN118178444A (zh) 2016-05-27 2024-06-14 吉利德科学公司 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
CN108368123B (zh) * 2016-07-08 2021-02-19 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
CN106220639A (zh) * 2016-07-22 2016-12-14 上海众强药业有限公司 一种维帕他韦中间体新晶型
CN107674063B (zh) * 2016-11-30 2020-03-27 上海博志研新药物技术有限公司 Gs5816中间体及制备方法和应用
JP7221277B2 (ja) 2017-08-28 2023-02-13 エナンタ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎抗ウイルス剤
CN107501280A (zh) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 一种维帕他韦的合成方法
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
JP2022507724A (ja) 2018-11-21 2022-01-18 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としての官能化複素環
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
WO2022040058A1 (en) * 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Cyclopentapyrrole orexin receptor agonists
US20220411434A1 (en) * 2021-05-21 2022-12-29 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2118069T3 (es) 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP4558314B2 (ja) * 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
KR101164070B1 (ko) 2003-05-09 2012-07-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
JP5676839B2 (ja) 2004-07-16 2015-02-25 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5314053B2 (ja) 2008-02-12 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2391600T3 (es) 2008-02-13 2012-11-28 Bristol-Myers Squibb Company Imidazoli bifenil imidazoles como inhibidores del virus de la hepatitis C
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
KR20110098779A (ko) 2008-12-03 2011-09-01 프레시디오 파마슈티칼스, 인코포레이티드 Ｈｃｖ ｎｓ5ａ의 억제제
CA2753313A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
BRPI1012282A2 (pt) 2009-03-27 2015-09-22 Presidio Pharmaceuticals Inc inibidores de anel fundidos da hepatite c.
US9139569B2 (en) 2009-05-12 2015-09-22 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
TWI689305B (zh) * 2009-05-13 2020-04-01 美商基利法瑪席特有限責任公司 抗病毒化合物
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
AU2011224698A1 (en) 2010-03-09 2012-11-01 Merck Sharp & Dohme Corp. Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2800530A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CA2809261A1 (en) 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
US8999967B2 (en) * 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
KR20190140486A (ko) * 2010-11-17 2019-12-19 길리애드 파마셋 엘엘씨 항바이러스 화합물
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
PT3431477T (pt) 2011-11-16 2020-12-15 Gilead Pharmasset Llc Imidazolilimidazolos condensados como compostos antivirais
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
US20130309196A1 (en) 2013-11-21
EP3239153B1 (en) 2019-05-08
PT3239153T (pt) 2019-07-30
JP2015517527A (ja) 2015-06-22
BR112014028221A2 (pt) 2020-10-27
JP6209209B2 (ja) 2017-10-04
AU2013262874A1 (en) 2014-12-11
EA028026B1 (ru) 2017-09-29
EP2850085B1 (en) 2017-03-15
WO2013173488A1 (en) 2013-11-21
IL235645A0 (en) 2015-02-01
ES2628350T3 (es) 2017-08-02
CN104487442B (zh) 2016-10-26
US20170342085A1 (en) 2017-11-30
CN106432254B (zh) 2018-12-28
AU2017248566A1 (en) 2017-11-09
CA2873485C (en) 2020-05-05
CN106432254A (zh) 2017-02-22
ES2738012T3 (es) 2020-01-17
SI3239153T1 (sl) 2019-08-30
EA034749B1 (ru) 2020-03-17
AU2013262874B2 (en) 2017-11-02
JP2017160276A (ja) 2017-09-14
EP2850085A1 (en) 2015-03-25
EA201492002A1 (ru) 2015-11-30
JP6408656B2 (ja) 2018-10-17
CN109970749A (zh) 2019-07-05
BR112014028221B1 (pt) 2022-05-03
PT2850085T (pt) 2017-06-26
US20140316144A1 (en) 2014-10-23
EA201790963A1 (ru) 2018-02-28
MX362060B (es) 2019-01-07
CN104487442A (zh) 2015-04-01
AU2019204423A1 (en) 2019-07-11
HK1205126A1 (en) 2015-12-11
KR20200017557A (ko) 2020-02-18
SG11201407533SA (en) 2014-12-30
EP3239153A1 (en) 2017-11-01
KR102078233B1 (ko) 2020-02-17
US10800789B2 (en) 2020-10-13
HK1245262B (zh) 2020-01-10
CA2873485A1 (en) 2013-11-21
US9682989B2 (en) 2017-06-20
PL3239153T3 (pl) 2019-09-30
SG10201703451RA (en) 2017-06-29
AU2013262874A2 (en) 2015-01-22
KR20150008908A (ko) 2015-01-23
SI2850085T1 (sl) 2017-08-31
US20190337960A1 (en) 2019-11-07
PL2850085T3 (pl) 2017-10-31
US20160115175A1 (en) 2016-04-28
MX2014013660A (es) 2015-04-17

Similar Documents

Publication Publication Date Title
IN2014MN02459A (es)
PH12015502839B1 (en) Antiviral compounds
SG190785A1 (en) Antiviral compounds
MX2019003738A (es) Compuestos antivirales.
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
EA201790781A3 (ru) Противовирусные соединения
NZ739760A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
IN2014CN04530A (es)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
GEP20156372B (en) Pyridazinone compounds and their use as daao inhibitors
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MY180006A (en) Azetidinyloxyphenylpyrrolidine compounds
IN2014MN01469A (es)
IN2013DN02555A (es)
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
NZ726343A (en) Antiviral compounds
MX337610B (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
IN2014DN07498A (es)
NZ725365A (en) Antiviral compounds inhibitors of hcv ns5b
GEP20156398B (en) Indazoles